Selected research
Industry Research
Biosimilar Insulin Glargine Industry Research Report 2026
Market perspective
The global Biosimilar Insulin Glargine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Biosimilar Insulin Glargine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Biosimilar Insulin Glargine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Biosimilar Insulin Glargine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Biosimilar Insulin Glargine include Biocon, Gan&Lee, Geropharm, United Laboratory, Wockhardt, Eli Lilly and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Biosimilar Insulin Glargine market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Biosimilar Insulin Glargine Market by Company
Biocon
Gan&Lee
Geropharm
United Laboratory
Wockhardt
Eli Lilly
Tonghua Dongbao
Biosimilar Insulin Glargine Segment by Type
Pre-filled
Cartridge
Biosimilar Insulin Glargine Segment by Application
Hospital
Retail Pharmacy
Others
Biosimilar Insulin Glargine Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biosimilar Insulin Glargine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Biosimilar Insulin Glargine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biosimilar Insulin Glargine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Biosimilar Insulin Glargine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Biosimilar Insulin Glargine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Biosimilar Insulin Glargine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Pre-filled
- Cartridge
Applications
- Hospital
- Retail Pharmacy
- Others
Companies covered
- Biocon
- Gan&Lee
- Geropharm
- United Laboratory
- Wockhardt
- Eli Lilly
- Tonghua Dongbao
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Biosimilar Insulin Glargine Market Size (2021-2032)
- 2.2.2 Global Biosimilar Insulin Glargine Sales (2021-2032)
- 2.2.3 Global Biosimilar Insulin Glargine Market Average Price (2021-2032)
- 2.3 Biosimilar Insulin Glargine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Pre-filled
- 2.3.3 Cartridge
- 2.4 Biosimilar Insulin Glargine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Retail Pharmacy
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Biosimilar Insulin Glargine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Biosimilar Insulin Glargine Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Biosimilar Insulin Glargine Revenue of Manufacturers (2021-2026)
- 3.4 Global Biosimilar Insulin Glargine Average Price by Manufacturers (2021-2026)
- 3.5 Global Biosimilar Insulin Glargine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Biosimilar Insulin Glargine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Biosimilar Insulin Glargine, Product Type & Application
- 3.8 Global Manufacturers of Biosimilar Insulin Glargine, Established Date
- 3.9 Global Biosimilar Insulin Glargine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Biocon
- 4.1.1 Biocon Company Information
- 4.1.2 Biocon Business Overview
- 4.1.3 Biocon Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Biocon Biosimilar Insulin Glargine Product Portfolio
- 4.1.5 Biocon Recent Developments
- 4.2 Gan&Lee
- 4.2.1 Gan&Lee Company Information
- 4.2.2 Gan&Lee Business Overview
- 4.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Gan&Lee Biosimilar Insulin Glargine Product Portfolio
- 4.2.5 Gan&Lee Recent Developments
- 4.3 Geropharm
- 4.3.1 Geropharm Company Information
- 4.3.2 Geropharm Business Overview
- 4.3.3 Geropharm Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Geropharm Biosimilar Insulin Glargine Product Portfolio
- 4.3.5 Geropharm Recent Developments
- 4.4 United Laboratory
- 4.4.1 United Laboratory Company Information
- 4.4.2 United Laboratory Business Overview
- 4.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 United Laboratory Biosimilar Insulin Glargine Product Portfolio
- 4.4.5 United Laboratory Recent Developments
- 4.5 Wockhardt
- 4.5.1 Wockhardt Company Information
- 4.5.2 Wockhardt Business Overview
- 4.5.3 Wockhardt Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Wockhardt Biosimilar Insulin Glargine Product Portfolio
- 4.5.5 Wockhardt Recent Developments
- 4.6 Eli Lilly
- 4.6.1 Eli Lilly Company Information
- 4.6.2 Eli Lilly Business Overview
- 4.6.3 Eli Lilly Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Eli Lilly Biosimilar Insulin Glargine Product Portfolio
- 4.6.5 Eli Lilly Recent Developments
- 4.7 Tonghua Dongbao
- 4.7.1 Tonghua Dongbao Company Information
- 4.7.2 Tonghua Dongbao Business Overview
- 4.7.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolio
- 4.7.5 Tonghua Dongbao Recent Developments
5 Global Biosimilar Insulin Glargine Market Scenario by Region
- 5.1 Global Biosimilar Insulin Glargine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Biosimilar Insulin Glargine Sales by Region: 2021-2032
- 5.2.1 Global Biosimilar Insulin Glargine Sales by Region: 2021-2026
- 5.2.2 Global Biosimilar Insulin Glargine Sales by Region: 2027-2032
- 5.3 Global Biosimilar Insulin Glargine Revenue by Region: 2021-2032
- 5.3.1 Global Biosimilar Insulin Glargine Revenue by Region: 2021-2026
- 5.3.2 Global Biosimilar Insulin Glargine Revenue by Region: 2027-2032
- 5.4 North America Biosimilar Insulin Glargine Market Facts & Figures by Country
- 5.4.1 North America Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Biosimilar Insulin Glargine Sales by Country (2021-2032)
- 5.4.3 North America Biosimilar Insulin Glargine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Biosimilar Insulin Glargine Market Facts & Figures by Country
- 5.5.1 Europe Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Biosimilar Insulin Glargine Sales by Country (2021-2032)
- 5.5.3 Europe Biosimilar Insulin Glargine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Biosimilar Insulin Glargine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Biosimilar Insulin Glargine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Biosimilar Insulin Glargine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Biosimilar Insulin Glargine Market Facts & Figures by Country
- 5.7.1 South America Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Biosimilar Insulin Glargine Sales by Country (2021-2032)
- 5.7.3 South America Biosimilar Insulin Glargine Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Biosimilar Insulin Glargine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Biosimilar Insulin Glargine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Biosimilar Insulin Glargine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Biosimilar Insulin Glargine Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Biosimilar Insulin Glargine Sales by Type (2021-2032)
- 6.1.1 Global Biosimilar Insulin Glargine Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Biosimilar Insulin Glargine Sales Market Share by Type (2021-2032)
- 6.2 Global Biosimilar Insulin Glargine Revenue by Type (2021-2032)
- 6.2.1 Global Biosimilar Insulin Glargine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Type (2021-2032)
- 6.3 Global Biosimilar Insulin Glargine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Biosimilar Insulin Glargine Sales by Application (2021-2032)
- 7.1.1 Global Biosimilar Insulin Glargine Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Biosimilar Insulin Glargine Sales Market Share by Application (2021-2032)
- 7.2 Global Biosimilar Insulin Glargine Revenue by Application (2021-2032)
- 7.2.1 Global Biosimilar Insulin Glargine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Application (2021-2032)
- 7.3 Global Biosimilar Insulin Glargine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Biosimilar Insulin Glargine Value Chain Analysis
- 8.1.1 Biosimilar Insulin Glargine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Biosimilar Insulin Glargine Production Mode & Process
- 8.2 Biosimilar Insulin Glargine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Biosimilar Insulin Glargine Distributors
- 8.2.3 Biosimilar Insulin Glargine Customers
9 Global Biosimilar Insulin Glargine Analyzing Market Dynamics
- 9.1 Biosimilar Insulin Glargine Industry Trends
- 9.2 Biosimilar Insulin Glargine Industry Drivers
- 9.3 Biosimilar Insulin Glargine Industry Opportunities and Challenges
- 9.4 Biosimilar Insulin Glargine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst